Preclinical strategies targeted at non-small-cell lung cancer signalling pathways with striking translational fallout

Roberto E. Favoni, Angela Alama

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Over the past decades, a plethora of cytotoxic agents, administered alone or in combinations, have been prescribed for the treatment of non-small-cell lung cancer (NSCLC) but improvements regarding patient outcome remain disappointing. Therefore, additional therapeutic strategies are urgently required to increase response rate and survival. By the time researchers had begun to understand the processes involved in NSCLC development, the genetic aetiology of lung cancer had been progressively defined. The constitutive activation of receptor tyrosine kinases and their downstream signalling pathways has opened encouraging avenues of investigation for NSCLC treatment. Several new targeted compounds have evolved from preclinical to clinical settings to affect growth factor pathways of NSCLC, and their therapeutic implications will be reviewed and discussed here.

Original languageEnglish
Pages (from-to)11-24
Number of pages14
JournalDrug Discovery Today
Volume18
Issue number1-2
DOIs
Publication statusPublished - Jan 2013

Fingerprint

Non-Small Cell Lung Carcinoma
Cytotoxins
Receptor Protein-Tyrosine Kinases
Therapeutics
Lung Neoplasms
Intercellular Signaling Peptides and Proteins
Survival Rate
Research Personnel

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology

Cite this

Preclinical strategies targeted at non-small-cell lung cancer signalling pathways with striking translational fallout. / Favoni, Roberto E.; Alama, Angela.

In: Drug Discovery Today, Vol. 18, No. 1-2, 01.2013, p. 11-24.

Research output: Contribution to journalArticle

@article{6aa6876c6885447284896d7b3230ad39,
title = "Preclinical strategies targeted at non-small-cell lung cancer signalling pathways with striking translational fallout",
abstract = "Over the past decades, a plethora of cytotoxic agents, administered alone or in combinations, have been prescribed for the treatment of non-small-cell lung cancer (NSCLC) but improvements regarding patient outcome remain disappointing. Therefore, additional therapeutic strategies are urgently required to increase response rate and survival. By the time researchers had begun to understand the processes involved in NSCLC development, the genetic aetiology of lung cancer had been progressively defined. The constitutive activation of receptor tyrosine kinases and their downstream signalling pathways has opened encouraging avenues of investigation for NSCLC treatment. Several new targeted compounds have evolved from preclinical to clinical settings to affect growth factor pathways of NSCLC, and their therapeutic implications will be reviewed and discussed here.",
author = "Favoni, {Roberto E.} and Angela Alama",
year = "2013",
month = "1",
doi = "10.1016/j.drudis.2012.07.011",
language = "English",
volume = "18",
pages = "11--24",
journal = "Drug Discovery Today",
issn = "1359-6446",
publisher = "Elsevier Limited",
number = "1-2",

}

TY - JOUR

T1 - Preclinical strategies targeted at non-small-cell lung cancer signalling pathways with striking translational fallout

AU - Favoni, Roberto E.

AU - Alama, Angela

PY - 2013/1

Y1 - 2013/1

N2 - Over the past decades, a plethora of cytotoxic agents, administered alone or in combinations, have been prescribed for the treatment of non-small-cell lung cancer (NSCLC) but improvements regarding patient outcome remain disappointing. Therefore, additional therapeutic strategies are urgently required to increase response rate and survival. By the time researchers had begun to understand the processes involved in NSCLC development, the genetic aetiology of lung cancer had been progressively defined. The constitutive activation of receptor tyrosine kinases and their downstream signalling pathways has opened encouraging avenues of investigation for NSCLC treatment. Several new targeted compounds have evolved from preclinical to clinical settings to affect growth factor pathways of NSCLC, and their therapeutic implications will be reviewed and discussed here.

AB - Over the past decades, a plethora of cytotoxic agents, administered alone or in combinations, have been prescribed for the treatment of non-small-cell lung cancer (NSCLC) but improvements regarding patient outcome remain disappointing. Therefore, additional therapeutic strategies are urgently required to increase response rate and survival. By the time researchers had begun to understand the processes involved in NSCLC development, the genetic aetiology of lung cancer had been progressively defined. The constitutive activation of receptor tyrosine kinases and their downstream signalling pathways has opened encouraging avenues of investigation for NSCLC treatment. Several new targeted compounds have evolved from preclinical to clinical settings to affect growth factor pathways of NSCLC, and their therapeutic implications will be reviewed and discussed here.

UR - http://www.scopus.com/inward/record.url?scp=84871928651&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871928651&partnerID=8YFLogxK

U2 - 10.1016/j.drudis.2012.07.011

DO - 10.1016/j.drudis.2012.07.011

M3 - Article

C2 - 22885521

AN - SCOPUS:84871928651

VL - 18

SP - 11

EP - 24

JO - Drug Discovery Today

JF - Drug Discovery Today

SN - 1359-6446

IS - 1-2

ER -